Bioelectronics Corp (BIEL)

[askjsell]

"2) BIEL has a 510k Premarket Notification for the ActiPatch in review with the FDA, decision due at any time

3) BIEL has more than doubled 2015 sales revenue over 2014 revenue"


The 510k is not under review any longer...why do you think the stock is selling off?

Also, sales increased....but the net loss got bigger! That is nuts. An increase in sales should reduce the net loss....but BIEL's net loss widened!